

Hansa Biopharma
P.O. Box 785
SE-220 07 Lund, Sweden
Phone: +46 46 16 56 70
Fax: +46 46 12 77 75

(Visiting address)
Scheelevägen 22
223 63 Lund, Sweden

www.hansabiopharma.com



Hansa Biopharma to Host Conference Call to Provide Second Quarter 2019 Business Update

On 18 July 2019, at 08:00 CET, Hansa Biopharma will publish its Business Update for the second quarter of 2019. All interested parties are invited to participate in a telephone conference, which will include a presentation, on the same day at 13:00 CET. The event will be hosted by Hansa Biopharma's CEO, Søren Tulstrup and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under Events & Webcast, and will also be made available online after the call. To participate in the telephone conference, please use the dial in details shown below:

SE: +46 850-558 352

UK: +44 3333 009 267

US: +1 833 823 0590

A link to audio cast can be found on the Hansa Biopharma website under Events & Webcasts or here:

<https://financialhearings.com/event/11685>

The information was submitted for publication, through the agency of the contact person set out below at 12:00 CET on July 5, 2019.

For further information, please contact:

Company:

Klaus Sindahl, Head of Investor Relations

Hansa Biopharma AB (publ)

Mobile: +46 (0) 709-298269

E-mail: klaus.sindahl@hansabiopharma.com

<http://hansabiopharma.com>

Rolf Gulliksen, Head of Corporate Communications

Hansa Biopharma AB (publ)

Mobile: +46 (0) 733-328 634

E-mail: rolf-gulliksen@hansabiopharma.com

<http://hansabiopharma.com>

About Hansa Biopharma

Hansa Biopharma AB (NASDAQ Stockholm: HNSA) is harnessing its proprietary immunomodulatory enzyme technology platform to develop treatments for rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection and cancer. The Company's lead product, IDEFIRIX (imlifidase), is a unique antibody-degrading enzyme in late-stage clinical development to enable kidney transplantation in highly sensitized patients, with additional clinical studies in acute autoimmune indications. Hansa's research and development program is advancing the next generation of the Company's technology to develop novel IgG-cleaving enzymes with lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Biopharma is based in Lund, Sweden.